Protego Biopharma raises $130M Series B for rare disease drug

Protego Biopharma, a clinical-stage rare disease biotech, raised a $130 million Series B round led by Novartis Venture Fund and Forbion.

What's next: Funds will help move Protego's lead drug candidate targeting AL amyloidosis into Phase 2 and 3 studies in late 2026, CEO Brent Warner tells Axios Pro.